Why the study?
PARADIGM-HF demonstrated the superiority of sacubitril/valsartan over enalapril in HF-REF, but how widely applicable this treatment is in unselected patients was not known.
What proportion of real-world patients with HFrEF are eligible for sacubitril/valsartan based on PARADIGM-HF criteria?
What proportion of real-world patients with HFrEF are eligible for sacubitril/valsartan based on PARADIGM-HF criteria?
A significant proportion (34-76%) of real-world HFrEF patients are eligible for sacubitril/valsartan, with low natriuretic peptide levels being the most common reason for ineligibility.
No takes yet. Share an insight, caveat, or question.
Eligibility assessment by background therapy may guide ARNI uptake in HFrEF; leaves open outcome impact and requires prospective validation.
Simpson et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: